The Final Chapter for Danimer Scientific: From Bioplastics Pioneer to Acquisition

Once hailed as a beacon of hope for biodegradable plastics, Danimer Scientific has ceased to exist as an independent public company. A dramatic sequence of events—plummeting share prices, a bankruptcy filing, and an eventual takeover—has removed the firm from the public markets. This marks the definitive conclusion for the former industry innovator.

The company's downfall culminated in a series of distinct, critical stages:

• Late 2024: Delisting from the New York Stock Exchange (NYSE) and a move to over-the-counter (OTC) trading.
• March 2025: A Chapter 11 bankruptcy petition filed amid severe liquidity constraints.
• June 2025: Complete acquisition by rival firm Teknor Apex.

Financial Struggles and Market Exit

The fundamental decline became unmistakable in late 2024. After persistently failing to meet the NYSE's minimum market capitalization requirements, the exchange initiated delisting procedures. A last-ditch effort to prop up the share price through a 1-for-40 reverse stock split proved entirely ineffective. Consequently, the equity lost its prestigious listing on Wall Street and was relegated to the unregulated OTCQX marketplace.

Should investors sell immediately? Or is it worth buying Danimer Scientific?

Bankruptcy and the End of Independence

The final financial reckoning arrived in March of the following year. Danimer Scientific filed for Chapter 11 protection. A combination of high expansion costs, underutilized production capacity, and a lack of substantial customer orders created an unsustainable cash crunch. As part of the restructuring process, plans to sell the company's assets were announced.

By June 2025, a resolution was reached. Competitor Teknor Apex stepped in to acquire Danimer Scientific in full. The primary objective was to integrate the sustainable materials technology into Teknor Apex's existing portfolio. This transaction formally terminated Danimer's operational independence.

As of February 2026, Danimer Scientific shares are no longer available for trading on any public market. With its business operations fully absorbed under the Teknor Apex corporate structure, no independent investment vehicle remains. The original stock market narrative has reached its terminus, offering no avenue for future trading activity.